In addition, increasing miR-21 levels were observed until there was a clinical progression under first-line TKI in EGFR-mutated NSCLC, anticipating TKI resistance and probably serving as MOR [191]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.